iifl-logo-icon 1
IIFL

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Lupin’s Swiss unit to acquire established product portfolio from Sanofi

22 Dec 2023 , 11:08 PM

Lupin Ltd stated on Friday that its wholly-owned subsidiary in Switzerland will purchase Sanofi PLC’s portfolio of accretive established pharmaceuticals in Europe.

Lupin Atlantis Holdings SA, Switzerland (LAHSA), a subsidiary of pharma giant Lupin, inked an ‘Asset Purchase Agreement’ with the French multinational pharmaceutical and healthcare firm Sanofi to purchase a portfolio of accretive established products in Europe and Canada.

AARANE in Germany and NALCROM in Canada and the Netherlands are among the brands bought by Lupin Atlantis Holdings SA, Switzerland, from Sanofi.

The acquisition of the two brands costs 10 million euros (about Rs 91 crore), plus sales milestones of up to 8 million euros (around Rs 72.8 crore), depending on future sales. The corporation told the exchanges that the transaction would be conducted in cash.

Lupin is acquiring these brands as part of a strategic interest in bringing accretive assets in the respiratory field to help structure the company’s new respiratory franchise in Germany, following the launch of Luforbec and Gx Spiriva, as well as the acquisition of the brands Xopenex and Brovana in the United States.

The purchase is subject to Foreign Direct Investment Bureau of Canada clearance and is scheduled to be finalised by the first quarter of 2024.

Lupin’s counter settled with a gain of 0.65% at Rs 1,265 per piece on NSE.

For feedback and suggestions, write to us at editorial@iifl.com

explored-media

Related Tags

  • Lupin
  • Lupin News
  • Lupin Swiss Arm
  • Lupin Updates
  • Sanofi
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Most Read News

Indian markets close on a positive note
14 Jun 2024|06:41 PM
Sensex and Nifty Surge
14 Jun 2024|06:43 PM
LIC stock price up by more than 5% today
14 Jun 2024|06:44 PM
Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.